SciELO - Scientific Electronic Library Online

 
vol.44 issue6The role and importance of SBRT in prostate cancer author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


International braz j urol

Print version ISSN 1677-5538On-line version ISSN 1677-6119

Int. braz j urol. vol.44 no.6 Rio de Janeiro Nov./Dec. 2018

http://dx.doi.org/10.1590/s1677-5538.ibju.2018.0459 

Letter to the Editor

Comment on ‘polygamy, sexual behavior in a population under risk for prostate cancer diagnostic: an observational study from the black sea region in Turkey’

Mete Özkidik1 

Anar İbrahimov2 

1Department of Urology, Sanliurfa Egitim ve Arastirma Hastanesi, Karşiyaka, Şanliurfa, Turkey

2Ankara university, Ankara, Turkey

To the editor,

I read the article by abdullah cirakoglu et al. (1) with great interest but i have some points of concern with this article.

Firstly, it is stated that all patients participated in the study have similar lifestyle and nutritional habits. However, the details of lifestyle and nutritional habits such as having office or night - shift work, consumption of processed meat or alcohol and smoking habits were not mentioned in the article. Also using hormonally active medications would be a predisposing factor for prostate cancer. Testosterone supplements (2) or 5 - alpha - reductase inhibitors (5 - ARIs) (3) are common examples currently under research whether leading to prostate cancer. The article does not reveal any details about the routine medications of the participants. On the other hand, I think, it would be rarely possible to say that all of 317 patients who were assessed in the study have similar lifestyles and nutritional habits even they used to live in the same geographical region.

Secondly, the increased number of sexual partners is under consideration in the article that it might be liable for having prostate cancer. I think it would be an important predisposing factor for prostate cancer due to causing chronic prostatitis which leads to prostatic intraepithelial atrophy (PIA) and than cancer in the long - term by recurrent sexually transmitted infections (STIs) (4). But the history of urethritis or prostatitis of the participants were not mentioned in the article. Although serologic testing could not be performed, questioning the history of urethritis would be beneficial. So, I think that considering only the number of sexual partners of the participants through their whole life would not be appropriate to determine the risk of prostate cancer unless the number or severity of attacks of prostatitis is considered.

Finally, sexual intercourse frequency is assessed in the study population as a risk factor for prostate cancer. Sexual intercourse frequency per month is compared between the two groups only for the youth and current period. But the limits of age for these periods are not determined in the article. In other words, it is not clear which decade is referred as considering “youth” or “current”. In addition, there is conflicting data about the association of ejaculation frequency (5) and prostate cancer in the current urologic literature. For some authors, the age of 30 is a critical point that ejaculation frequency in younger ages and older ages have different impacts on development of prostate cancer. So I believe that the period of age should also be mentioned in the article as well as the frequency of sexual intercourse as considering the risk of prostate cancer.

REFERENCES

1. Cirakoglu A, Benli E, Yuce A. Polygamy, sexual behavior in a population under risk for prostate cancer diagnostic: an observational study from the Black Sea Region in Turkey. Int Braz J Urol. 2018;44:704-8. [ Links ]

2. Haider A, Zitzmann M, Doros G, Isbarn H, Hammerer P, Yassin A. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. J Urol. 2015;193:80-6. [ Links ]

3. Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, et al. Use of 5 - alpha - reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology / American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol. 2009;27:1502-16. Erratum in: J Clin Oncol. 2009;27:2742.68556. [ Links ]

4. Lian WQ, Luo F, Song XL, Lu YJ, Zhao SC. Gonorrhea and Prostate Cancer Incidence: An Updated Meta-Analysis of 21 Epidemiologic Studies. Med Sci Monit. 2015;21:1902-10. [ Links ]

5. Rider JR, Wilson KM, Sinnott JA, Kelly RS, Mucci LA, Giovannucci EL. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. 2016;70:974-982. [ Links ]

Received: July 09, 2018; Accepted: July 22, 2018; pub: September 20, 2018

Correspondence address: Mete Özkidik, MD, Department of Urology, Sanliurfa Egitim ve Arastirma Hastanesi 498, Street 5A, 15 Karşiyaka Şanliurfa, Sanliurfa, 63850, Turkey E-mail: meteozkd@gmail.com

Creative Commons License This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.